模拟移动床色谱法拆分甲霜灵对映体

模拟移动床(SMB)色谱作为一种精确、高效的制备色谱技术引起研究者的极大关注。本文以EnantioPak OD填料为手性固定相,正己烷-乙醇(70 : 30, v/v)为流动相,在四区模拟移动床上手性拆分甲霜灵外消旋体。采用旋光检测器研究甲霜灵异构体在手性柱上的洗脱顺序;探讨进样浓度、进样流速、各区流速和切换时间等条件对手性分离甲霜灵外消旋体的影响,并与制备色谱进行比较。结果表明:S-(+)-甲霜灵先于R-(-)-甲霜灵被流动相洗脱,R-(-)-甲霜灵在色谱柱上的保留强于S-(+)-甲霜灵;在线性和非线性条件下,模拟移动床都能很好地拆分甲霜灵外消旋体,在优化SMB工艺条件下,S-(+)-甲霜灵和R-(-)-甲霜灵的光学纯度都大于99%;在样品质量浓度为15 mg/mL的条件下,模拟移动床色谱分离的样品量显著高于制备色谱,而流动相消耗仅为后者的1/9。这对于发展大规模色谱拆分甲霜灵工艺具有良好的指导意义。     

动态液相微萃取GC/MS-SIM方法检验毛发中的苯丙胺类毒品

建立了动态液相微萃取GC/MS-SIM方法检测毛发中4种苯丙胺类毒品的方法.毛发样品首先用1 mol/L NaOH溶液消解,然后用50μL氯仿涡旋提取1min,离心后用注射器直接抽取有机相,提取液进行GC/MS-SIM方法检测.毛发样品的测出限(S/N=3)分别为苯丙胺1 ng/mg,甲基苯丙胺、3、4-(亚甲二氧基)苯丙胺、3、4(亚甲二氧基)-甲基苯丙胺500 pg/mg.在毛发中添加上述4种苯丙胺毒品的质量分数为5 ng/mg时,5次测定的RSD分别为苯丙胺8.3%,甲基苯丙胺8.2%,3、4-(亚甲二氧基)苯丙胺2.0%,3、4(亚甲二氧基)2.7%.该方法可用于毛发中低含量苯丙胺类毒品的分析.     

动态液相微萃取-微波衍生化-气相色谱/选择离子检测-质谱法测定毛发中的苯丙胺类毒品

建立了一种便捷的毛发中4种苯丙胺毒品的检测方法。采用动态液相微萃取法用氯仿提取毛发消解液中的苯丙胺类毒品,然后在微波加热的条件下用N-甲基-双三氟乙酰胺(MBTFA)进行衍生化处理,将反应液直接用气相色谱/选择离子检测-质谱法（GC/SIM-MS）检测。以2-甲基苯乙胺为内标,在空白毛发中添加标准品做标准曲线得到4种苯丙胺类毒品的线性相关系数均不小于0.996。衍生化后4种毒品在毛发中的最小检测限(S/N=3)均为50 pg/mg。4种苯丙胺类毒品在毛发中的添加浓度为5 ng/mg时,5次测定的相对标准偏差（RSD）分别为苯丙胺6.0%,甲基苯丙胺13.9%,3,4-(亚甲二氧基)苯丙胺10.2%,3,4(亚甲二氧基)-甲基苯丙胺9.2%。应用所建立的方法对苯丙胺类毒品吸食者的毛发进行检测,检出了这4种毒品,毛发样品的最小用量为4.6 mg (约20 cm 长)。该方法灵敏、简便、快速,可用于毛发中低含量苯丙胺类毒品的分析。     

由孕甾-3S,5R,6R,16S,20S-五醇合成黄体酮

首次利用薯蓣皂甙元降解产物, 孕甾-3S,5R,6R,16S,20S-五醇(3)完成了黄体酮的合成. 孕甾-3S,5R,6R,16S,20S-五醇可方便地通过薯蓣皂甙元经由30%双氧水原地产生的过酸氧化降解得到. 它经过缩酮化反应、乙酰化反应和串联的脱缩酮-溴代乙酰化反应被转化成关键合成中间体16R-溴孕甾-3S,5R,6R,20S-四醇-3,6,20-三乙酸酯(6). 化合物6经锌粉还原、C-3乙酰氧基选择性水解氧化反应和C-5羟基消除反应生成6R,20S-二乙酰氧基孕甾-4-烯-3-酮(10). 化合物10经C-6乙酰氧基还原和C-20乙酰氧基水解-氧化生成目标分子黄体酮. 合成经10步反应, 反应总收率达45.1%.     

超声提取-超高效液相色谱-串联质谱法测定毛发中常见毒品及代谢物的含量

建立了超声提取-超高效液相色谱-串联质谱法（UHPLC-MS/MS）测定毛发中常见毒品及代谢物含量的方法。称取洗涤（水、二氯甲烷、丙酮依次振荡洗涤各1次）并晾干后的毛发样品40～60 mg,将其剪成约1 mm小段,加入3.2 mm的破碎珠6颗,冷冻破碎5 min;再称取破碎后的毛发样品20 mg,加入1 mL甲醇,于0℃冰水浴中超声提取20 min,上清液用0.25μm有机滤膜过滤,滤液供UHPLC-MS/MS测定。结果显示：O⁶-单乙酰吗啡（6-AM）、吗啡（MOR）、氯胺酮（K粉）、甲基苯丙胺（MAMP）、苯丙胺（AMP）、可卡因（COC）、苯甲酰爱康宁（BZE）、3,4-亚甲双氧甲基苯丙胺（MDMA）、3,4-亚甲双氧苯丙胺（MDA）、3,4-亚甲双氧乙基苯丙胺（MDEA）、可待因（COD）、去甲氯胺酮（NK）、Δ⁹-四氢大麻酚（THC）、大麻二酚（CBD）、大麻酚（CBN）等15种目标物的质量分数在一定范围内与其对应的峰面积呈线性关系,BZE、THC、CBD、COC、CBN的检出限（3S/N）均为0.001 ng·mg^-1<...     

高效液相色谱手性流动相添加法拆分阿卓乳酸对映体

采用C₁₈反相色谱柱,以磺丁基醚-β-环糊精（SBE-β-CD）作为手性流动相添加剂,建立了阿卓乳酸对映体的高效液相色谱拆分方法。考察了环糊精衍生物类型、手性添加剂浓度、流动相pH、流速和柱温对手性分离的影响,同时探讨了高效液相色谱采用磺丁基醚-β-环糊精分离阿卓乳酸对映体的分离机制及包结常数,确定了色谱条件为YMC-Pack ODS-A C₁₈色谱柱（250 mm×4.6 mm,5 μm）,流动相为含25 mmol/LSBE-β-CD的0.1 mol/L磷酸盐缓冲液（pH 2.68）-乙腈（90：10,v/v）,流速为0.6 mL/min,柱温为30 ℃,紫外检测波长为220 nm。对映体的保留时间分别为26.65和28.28 min,分离度为1.68。本方法分离度好,简便易行,且比使用手性固定相分离更加经济。     

免疫亲和固相萃取-超高效合相色谱-串联质谱法同时测定牛奶中6种玉米赤霉醇类化合物残留

建立了免疫亲和固相萃取（IAC-SPE）-超高效合相色谱-串联质谱（UPC²-MS/MS）同时测定牛奶中α-玉米赤霉醇、β-玉米赤霉醇、α-玉米赤霉烯醇、β-玉米赤霉烯醇、玉米赤霉烯酮和玉米赤霉酮残留的分析方法。样品用去离子水稀释,经IAC-SPE富集净化后,采用Waters ACQUITY UPC² Torus 2-PIC色谱柱（50 mm×3.0 mm,1.7 μm）分离,以超临界CO₂和0.1%（v/v）甲酸甲醇溶液为流动相,经梯度洗脱后在ESI^-模式下检测。经过稀释离心的牛奶样品采用免疫亲和柱净化后没有明显的基质效应,6种目标化合物在1~200 ng/mL范围内线性关系良好,相关系数（r²）≥0.9957;6种目标化合物在3个加标水平下的平均回收率为75.9%~106.5%,日内和日间精密度均≤11.4%。该法专属性好,操作简便,有机溶剂使用量小,与已有的样品测定方法比较更绿色环保,可用于牛奶中α-玉米赤霉醇、β-玉米赤霉醇、α-玉米赤霉烯醇、β-玉米赤霉烯醇、玉米赤霉酮和玉米赤霉烯酮的残留检测。     

气相色谱-质谱法测定酱猪蹄和酱猪肘中5种胆固醇氧化物

建立了气相色谱-质谱（GC-MS）测定酱猪蹄和酱猪肘中7 β-羟基胆固醇、5 α，6 α-环氧化胆固醇、胆甾烷-3 β，5 α，6 β-三醇、25-羟基胆固醇和7-酮基胆固醇5种胆固醇氧化物（COPs）含量的方法。样品经甲醇-氯仿（1：2，v/v）混合溶液提取，硅胶固相萃取小柱净化后，加入N，O-双（三甲基硅基）乙酰胺-三甲基氯硅烷-三甲基硅基咪唑（3：2：3，v/v/v）（Sylon BTZ）进行衍生化处理，设置合理的柱温升温程序，采用选择离子扫描（SIM）模式进行检测。在优化条件下，5种COPs在22 min内实现分离，且分离度良好。5种COPs的线性范围满足测定要求，3个加标水平下的平均回收率为61.16%~96.96%，相对标准偏差≤ 7.80%（n=3），检出限（以信噪比为3计）和定量限（以信噪比为10计）分别为0.02~47.07 ng/g和0.06~156.90 ng/g。该法快速简便，线性范围广，灵敏度高，可作为测定实际样品中COPs的有效方法。     

维生素C抗氧化-同位素内标稀释-超高效液相色谱-串联质谱同时测定新生期大鼠海马体神经递质的含量

脑区神经递质的测定对于研究神经系统的作用机制具有重要意义。该研究建立了同位素内标稀释-超高效液相色谱-串联质谱同时测定双酚A暴露后大鼠海马体中5种神经递质含量的方法，包括谷氨酸、γ-氨基丁酸、乙酰胆碱、多巴胺以及5-羟色胺。选用2%（体积分数）乙酸水-甲醇（9：1，v/v）溶液配制标准样品及溶解样品，以Ultimate AQ-C₁₈（150 mm×4.6 mm，3 μ m）为分离柱，0.1%（体积分数）甲酸水和甲醇为流动相，在28℃柱温下，梯度洗脱，所有化合物在3 min内出峰。添加维生素C能显著减少多巴胺和5-羟色胺在前处理以及样品储存过程中的氧化，极大地提高神经递质的稳定性，从而准确定量。该方法标准曲线线性关系良好，相关系数R²>0.998，检出限和定量限低，日内和日间精密度为0.39%~13.6%，加标回收率为92.9%~119%，实际进样残留低，已被成功地应用于新生期双酚A暴露后大鼠海马体神经递质含量的测定。     

通过式固相萃取-超高效液相色谱-串联质谱法测定水产品中地西泮

建立了通过式固相萃取-超高效液相色谱-串联质谱测定水产品中地西泮残留量的分析方法。样品用乙腈直接提取，经Prime HLB通过式固相萃取柱（60 mg/3 mL）净化，以Acquity UPLC BEH C₁₈（100 mm×2.1 mm，1.7 μm）为色谱柱，甲醇-0.1%（v/v）甲酸水溶液为流动相进行梯度洗脱。在多反应监测（MRM）、正离子电离模式下检测，采用基质匹配标准曲线外标法进行定量分析。结果显示：在0.1~10 ng/mL范围内，地西泮线性关系良好（r²>0.99）。在1.5、3.0和15.0 μg/kg 3个加标水平下，地西泮的加标回收率为88.2%~101.1%，日间和日内精密度（RSD）均在10%以下。该法简便快速，灵敏度高，可用于水产品中地西泮的准确测定。     

Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application

A novel, fast and sensitive enantioselective HPLC assay with a new core–shell isopropyl carbamate cyclofructan 6 (superficially porous particle, SPP) chiral column (LarihcShell-P, LSP) was developed and validated for the enantiomeric separation and quantification of verapamil (VER) in rat plasma. The polar organic mobile phase composed of acetonitrile/methanol/trifluoroacetic acid/triethylamine (98:2:0.05: 0.025, v/v/v/v) and a flow rate of 0.5 mL/min was applied. Fluorescence detection set at excitation/emission wavelengths 280/313 nm was used and the whole analysis process was within 3.5 min, which is 10-fold lower than the previous reported HPLC methods in the literature. Propranolol was selected as the internal standard. The S-(−)- and R-(+)-VER enantiomers with the IS were extracted from rat plasma by utilizing Waters Oasis HLB C18 solid phase extraction cartridges without interference from endogenous compounds. The developed assay was validated following the US-FDA guidelines over the concentration range of 1–450 ng/mL (r² ≥ 0.997) for each enantiomer (plasma) and the lower limit of quantification was 1 ng/mL for both isomers. The intra- and inter-day precisions were not more than 11.6% and the recoveries of S-(−)- and R-(+)-VER at all quality control levels ranged from 92.3% to 98.2%. The developed approach was successfully applied to the stereoselective pharmacokinetic study of VER enantiomers after oral administration of 10 mg/kg racemic VER to Wistar rats. It was found that S-(−)-VER established higher C_max and area under the concentration-time curve (AUC) values than the R-(+)-enantiomer. The newly developed approach is the first chiral HPLC for the enantiomeric separation and quantification of verapamil utilizing a core–shell isopropyl carbamate cyclofructan 6 chiral column in rat plasma within 3.5 min after solid phase extraction (SPE).     

Enantioanalysis of bisoprolol in human plasma with a macrocyclic antibiotic HPLC chiral column using fluorescence detection and solid phase extraction

A sensitive, enantioselective, high-performance liquid chromatographic (HPLC) method was developed and validated to determine S-(-)- and R-(+)-bisoprolol in human plasma. Baseline resolution was achieved using the teicoplanin macrocyclic antibiotic chiral stationary phase (CSP) known as Chirobiotic T with a polar ionic mobile phase (PIM) consisting of methanol-glacial acetic acid-triethylamine (100 : 0.02 : 0.025, v/v/v) at a flow rate of 1.5 ml/min and fluorescence detection set at 275 nm for excitation and 305 nm for emission. All analyses with S-(-)-atenolol as the internal standard were conducted at ambient temperature. The assay involved the use of a solid-phase extraction procedure for human plasma samples prior to HPLC analysis. The C18 cartridge gave good recovery rates for both enantiomers without any interference. The method was validated over the range of 20-200 ng/ml for each enantiomer concentration. Recovery rates for S-(-)- and R-(+)-bisoprolol enantiomers were in the range of 95-102%. The method proved to be precise (within-run precision expressed as % RSD ranged from 1.0-6.2% and between-run precision ranged from 0.9-6.7%) and accurate (within-run accuracies expressed as percentage error ranged from 0.2-4.8% and between-run accuracies ranged from 0.3-1.7%). The limit of quantitation and limit of detection for each enantiomer in human plasma were 20 and 5 ng/ml, respectively.     

Determination of the enantiomeric impurity in S-(-)pantoprazole using high performance liquid chromatography with sulfobutylether-beta-cyclodextrin as chiral additive

A new and accurate HPLC method using sulfobutylether-beta-cyclodextrin (SBE-beta-CD) as chiral mobile phase additive (CMPA) was developed and validated for the determination of R-(+)pantoprazole in S-(-)pantoprazole. The influences of type and concentration of CD, ACN content and buffer pH of mobile phase on the resolution and retention of enantiomers were investigated. A baseline resolution of pantoprazole enantiomers was achieved on a Spherigel C18 column (150 mm x 4.6 mm, 5 microm) using ACN and 10 mM phosphate buffer (pH 2.5) containing 10 mM SBE-beta-CD (15:85 v/v) as mobile phase with a flow rate of 0.9 mL/min at 20 degrees C. The detection wavelength was set at 290 nm. The method was extensively validated in terms of accuracy, precision and linearity according to the International Conference on Harmonisation (ICH) guidelines and proved to be robust. The LOD and LOQ for R-(+)pantoprazole were 0.2 and 0.5 microg/mL, respectively, with 5 microL injection volume. A good linear relationship was obtained in the concentration range of 0.5-6.0 microg/mL with r(2) >0.999 for R-(+)pantoprazole. The percentage recovery of the R-(+)pantoprazole ranged from 92.1 to 101.2 in bulk drug of S-(-)pantoprazole. The method is capable of determining a minimum limit of 0.05% w/w of R-enantiomer in S-(-)pantoprazole bulk samples.     

Characterization of the stereoselective metabolism of thiopental and its metabolite pentobarbital via analysis of their enantiomers in human plasma by capillary electrophoresis.

Using capillary zone electrophoresis (CZE) with a 75 mM phosphate buffer at pH 8.5 containing 5 mM hydroxypropyl-gamma-cyclodextrin (OHP-gamma-CD) as chiral selector, the separation of the enantiomers of thiopental and its oxybarbiturate metabolite, pentobarbital, is reported. Enantiomer assignment was performed via preparation of enantiomerically enriched fractions using chiral recycling isotachophoresis (rITP) processing of racemic barbiturates and analysis of rITP fractions by chiral CZE and circular dichroism spectroscopy. Thiopental and pentobarbital enantiomers in plasma were extracted at low pH using dichloromethane and extracts were reconstituted in acetonitrile or 10-fold diluted, achiral running buffer. The stereoselectivity of the thiopental and pentobarbital metabolism was assessed via analysis of 12 plasma samples that stemmed from patients undergoing prolonged or having completed long-term racemic thiopental infusion. The data obtained revealed a modest stereoselectivity with R-(+)-thiopental/S-(-)-thiopental and R-(+)-pentobarbital/S-(-)-pentobarbital plasma ratios being < 1 (P < 0.05 compared to data obtained with racemic controls) and > 1 (P < 0.001), respectively. The total S-(-)-thiopental plasma concentration was found to be on average about 24% higher compared to the concentration of R-(+)-thiopental, whereas the total R-(+)-pentobarbital plasma level was observed to be on average 29% higher compared to the S-(-)-pentobarbital concentration.     

Enantioselective determination of arotinolol in human plasma by HPLC using teicoplanin chiral stationary phase

A sensitive enantioselective high-performance liquid chromatography (HPLC) method was developed and validated to determine S-(+)- and R-(-)-arotinolol in human plasma. Baseline resolution was achieved by using teicoplanin macrocyclic antibiotic chiral stationary phase (CSP) known as Chirobiotic T with a polar organic mobile phase consisting of methanol:glacial acetic acid:triethylamine, 100:0.1:0.1, (v/v/v) at a fl ow rate of 0.8 mL/min and UV detection set at 317 nm. Human plasma was spiked with stock solution of arotinolol enantiomers and labetalol as the internal standard. The assay involved the use of liquid-liquid extraction procedure with ethyl ether under alkaline condition for human plasma sample prior to HPLC analysis. Recoveries for S-(+)- and R-(-)-arotinolol enantiomers were in the range 93-103% at 200-1400 ng/mL level. Intra-day and inter-day precision calculated as %RSD was in the ranges 1.3-3.4 and 1.9-4.5% for both enantiomers, respectively. Intra-day and inter-day accuracies calculated as percentage error were in the ranges 1.2-3.5 and 1.5-6.2% for both enantiomers, respectively. Linear calibration curves in the concentration range 100-1500 ng/mL for each enantiomer showed a correlation coefficient (r) of 0.9998. The limit of quantitation (LOQ) and limit of detection (LOD) for each enantiomer in human plasma were 100 and 50 ng/mL (S/N = 3), respectively.     

Simultaneous quantitative determination of amphetamines, ketamine, opiates and metabolites in human hair by gas chromatography/mass spectrometry

A gas chromatography/mass spectrometry (GC/MS) method was developed and validated for the determination of common drugs of abuse in Asia. The method was able to simultaneously quantify amphetamines (amphetamine; AP, methamphetamine; MA, methylenedioxy amphetamine; MDA, methylenedioxymeth mphetamine; MDMA, methylenedioxy ethylamphetamine; MDEA), ketamine (ketamine; K, norketamine; NK), and opiates (morphine; MOR, codeine; COD, 6-acetylmorphine; 6-AM) in human hair. Hair samples (25 mg) were washed, cut, and incubated overnight at 25 degrees C in methanol/trifluoroacetic acid (methanol/TFA). The samples were extracted by solid-phase extraction (SPE), derivatized using heptafluorobutyric acid anhydride (HFBA) at 70 degrees C for 30 min, and the derivatives were analyzed by electron ionization (EI) GC/MS in selected ion monitoring mode. Confirmation was accomplished by comparing retention times and the relative abundances of selected ions with those of standards. Deuterated analogs of the analytes were used as internal standards for quantification. Calibration curves for ten analytes were established in the concentration range 0.1-10 ng/mg with high correlation coefficients (r2 > 0.999). The intra-day and inter-day precisions were within 12.1% and 15.8%, respectively. The intra-day and inter-day accuracies were between -8.7% and 10.7%, and between -5.9% and 13.8%, respectively. The limit of detection (LOD) and limit of quantification (LOQ) obtained were 0.03 and 0.05 ng/mg for AP, MA, MDA, MDMA and MDEA; 0.05 and 0.08 ng/mg for K, NK, MOR and COD; and 0.08 and 0.1 ng/mg for 6-AM. The recoveries were above 88.6% for all the compounds, except K and NK which were in the range of 71.7-72.7%. Eight hair samples from known polydrug abusers were examined by this method. These results show that the method is suitable for broad-spectrum drug testing in a single hair specimen.     

Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry

A sensitive method using enantiospecific liquid chromatography/tandem mass spectrometry detection for the quantitation of S- and R-mephenytoin as well as its metabolites S- and R-nirvanol and S- and R-4'-hydroxymephenytoin in plasma and urine has been developed and validated. Plasma samples were prepared by protein precipitation with acetonitrile, while urine samples were diluted twice with the mobile phase before injection. The analytes were then separated on a chiral alpha(1)-acid glycoprotein (AGP) column and thereafter detected, using electrospray ionization tandem mass spectrometry. In plasma, the lower limit of quantification (LLOQ) was 1 ng/mL for S- and R-4'-hydroxymephenytoin and S-nirvanol and 3 ng/mL for R-nirvanol and S- and R-mephenytoin. In urine, the LLOQ was 3 ng/mL for all compounds. Resulting plasma and urine intra-day precision values (CV) were <12.4% and <6.4%, respectively, while plasma and urine accuracy values were 87.2-108.3% and 98.9-104.8% of the nominal values, respectively. The method was validated for plasma in the concentration ranges 1-500 ng/mL for S- and R-4'-hydroxymephenytoin, 1-1000 ng/mL for S-nirvanol, and 3-1500 ng/mL for R-nirvanol and S- and R-mephenytoin. The validated concentration range in urine was 3-5000 ng/mL for all compounds. By using this method, the metabolic activities of two human drug-metabolizing enzymes, cytochrome P450 (CYP) 2C19 and CYP2B6, were simultaneously characterized.     

Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies.

In order to be able to measure low concentrations of tranylcypromine enantiomers in biological material, chiral fluorescent derivatization and high-performance liquid chromatography (HPLC) were employed. The internal standard S-(+)-amphetamine and borate-sodium hydroxide buffer pH 11 were added to plasma or urine sample aliquots. o-Phthaldialdehyde was used for precolumn derivatization in combination with the chiral mercaptan N-acetylcysteine. HPLC resolution of the diastereoisomeric derivatives was possible on an octadecylsilane column. The mobile phase consisted of sodium phosphate buffer solution pH 6.5, methanol and tetrahydrofuran. The fluorescence of the eluate was monitored at 344/442 nm. The intra-day coefficients of variation were below 10%, the limit of determination was 0.5 ng/ml. The assay was found to be applicable for routine analyses in a preliminary pharmacokinetic study, in which an oral dose of 20 mg racemic tranylcypromine sulfate was administered to three healthy volunteers. The plasma concentrations were generally low, and those of S-(-)-tranylcypromine significantly exceeded those of the R-(+)-enantiomer. Average maximum concentrations were 57.5 and 6.3 ng/ml for S- and R-tranylcypromine, respectively. While S-tranylcypromine was well detectable within the whole study period (8 h), R-tranylcypromine concentrations fell below the detection limit after 4 h in two out of the three studied volunteers.     

Determination of saterinone enantiomers in plasma samples with an internal standard using a Chiralcel OD column, fractionation and reversed-phase chromatography

A specific and validated high-performance liquid chromatographic method was developed for the determination of the S-(-) and R-(+) enantiomers of saterinone. 1-[(4-cyano-1,2-dihydro-6-methyl-2-oxopyridin-5-yl)phenoxyl] -3-[4-(2- methoxyphenyl)piperazin-1-yl]propan-2-ol, in plasma at the low ng/ml level. The enantiomers of saterinone and an internal standard, 1-[(4-cyano-1,2-dihydro-6-methyl-2-oxo-pyridin-5-yl)phenoxy]-3-[4-(2- ethoxyphenyl)piperazin-1-yl]propan-2-ol, were chromatographed on a chiral Chiralcel OD stationary phase. However, the S-(-) enantiomers of saterinone and the internal standard were unresolved, as were the R-(+) enantiomers of both substances. Therefore, the two fractions were collected and each was separately resolved on an achiral Polyencap A reversed-phase column and quantified. The detection limit was 0.5 ng/ml of enantiomer, allowing the determination of plasma levels up to 36 h after oral administration of 90, 150 and 180 mg of saterinone to twelve subjects.     

Enantiomeric separation and quantification of pindolol in human plasma by chiral liquid chromatography/tandem mass spectrometry using staggered injection with a CTC Trio Valve system

Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) for the treatment of cardiovascular diseases such as hypertension and angina pectoris. It has one chiral center, and, therefore, two optical isomers. It was essential to develop an enantioselective assay to measure each enantiomer in human plasma. However, separation of enantiomers using chiral chromatography usually requires relatively long retention times. This can pose a problem for rapid turnaround of a large number of samples (i.e., clinical studies). In the present study, a simple and sensitive chiral liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) method was developed and validated for the determination of S-(-)- and R-(+)-pindolol in human plasma. To increase throughput, staggered sample injection was employed using a CTC Trio Valve system on a CTC HTS PAL autosampler. The method exhibited good intra- and inter-day accuracy and precision, and was linear over a dynamic range of 250 pg/mL to 250 ng/mL for each pindolol enantiomer. Intra- and inter-day accuracy ranged between 90.0-106% and 91.6-104% for both quality control (QC) samples of S-(-)- and R-(+)-pindolol, respectively. The respective intra- and inter-day precision ranged between 4.24-7.86% and 4.98-10.4%.